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1 Abstract 
Objective: Few epidemiological studies have addressed the health of workers exposed to 
novel manufactured nanomaterials. The small current workforces will necessitate pooling 
international cohorts. Method: A roadmap was defined for a globally harmonized framework 
for the careful choice of materials, exposure characterisation, identification of study 
populations, definition of health endpoints, evaluation of appropriateness of study designs, 
data collection and analysis, and interpretation of the results. Results: We propose a 
roadmap to reach global consensus on these issues. The proposed strategy should ensure 
that the costs of action are not disproportionate to the potential benefits, and that the 
approach is pragmatic and practical. Conclusions: We should aim to go beyond the collection 
of health complaints, illness statistics or even counts of deaths: the manifestation of such 
clear endpoints would indicate a failure of preventive measures. 
2 Clinical significance 
Epidemiological research is needed to confirm that proposed protective measures are 
effective. This roadmap proposes a strategy to assess materials, exposure, health endpoints, 
populations, ethical-societal aspects, study designs, data collection and analysis, and 
interpretation of the results while ensuring that the approach is cost-efficient, pragmatic and 
practical. 
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3 Why harmonize world-wide? 
Nanomaterials, due to their novel physico-chemical properties, are making their way into 
businesses and products. After a phase of "nano-hype" with few concrete nanomaterials 
applications, development of real-life products and processes including nanomaterials is now 
progressing steadily. Already today, about 1% of all companies are involved with 
nanomaterial production or development (1, 2), although each of them only has a few 
workers actually dealing with nanomaterials. However, with the growing number of existing 
and novel nanomaterials, and their applications and incorporation in products, an increasing 
number of workers is expected to become exposed to these materials throughout the 
products' life cycles. In anticipation of this growing market, and in response to debates about 
the potential health risks of nanomaterials, research is being carried out worldwide in an 
effort to ensure that there are no adverse health effects from working with nanomaterials (3). 
The early identification of potential health and safety issues indeed allows us to redirect 
investments for safer future steps in technology development.  
Most current research projects in this field focus on exposure measurement techniques and 
toxicological research that identifies mechanisms of effect and no adverse effect levels in test 
systems (4). However, occupational health studies of exposed nanomaterial workers are 
needed to confirm that the derived levels are safe and that the applied safety and preventive 
health measures are effective. Epidemiological studies of the health of workers producing 
and using the classic carbon black and amorphous silica nanomaterials were carried out in 
the late 1980s/mid 1990s (5, 6). However, the workforce in individual countries and 
companies (1, 7) is still small, and there is a large diversity of nanomaterials, which poses 
challenges for the recruitment of sufficiently large cohorts. This leads to the necessity for 
pooling cohorts internationally for consideration of novel nanomaterials. The implementation 
of such studies is currently hampered by: i) few standardised, accurate and reliable 
approaches for estimating exposure; ii) large variability in nanomaterial metrics and co-
exposures; iii) the lack of information on health effects and biomarkers; iv) lack of large 
production forces in this emerging industry, rather a considerable proportion in research and 
development; v) questionable statistical power related to currently small workforce sizes and 
short latency for disease occurrence; and v) a changing regulatory framework without 
harmonized registration systems for workers employed in these industries (8). 
Numerous different approaches could be taken for monitoring the health effects of 
nanomaterials, including occupational health reporting schemes, health surveillance, health 
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risk appraisal surveys and self-reporting questionnaires (3, 9, 10). Acceptability of different 
approaches will be strongly influenced by the social contexts and regulatory backgrounds in 
different countries. These determine where responsibilities lie, and who ensures that the 
required steps in both exposure assessment and health effect monitoring are implemented. 
In this report, the most pressing needs in terms of global harmonization were identified as 
follows: 
(a) Outline the range of information necessary for epidemiological studies in 
nanomaterial workers; 
(b) Evaluate exposure data and models useful for pooled exposure assessments and 
provide task-based exposure profiles for specific nanomaterials; 
(c) Link different worker activities and task profiles to job titles, job descriptions, and 
industries on the one hand and to production processes on the other;  
(d) Evaluate health effects and biomarkers for use in future occupational health 
reporting schemes and epidemiological studies, based on knowledge derived 
from toxicology studies of the subject nanomaterial and inference from 
epidemiological studies of other nanomaterials; 
(e) Define the requirements for epidemiological studies and identify suitable cohorts; 
(f) Provide recommendations for small and medium enterprises (SMEs) and 
associated organisations regarding early assessment and management of 
possible risks for nanomaterial workers and the setup of exposure and health 
effect registries. 
Consequently, the rationale for creating this is that before embarking on any large-scale, 
human-health monitoring studies, it is of paramount importance to determine their feasibility 
and whether they will ensure useful, reliable results. Basic preparatory work is thus needed 
to evaluate and analyse existing knowledge, data, and practices for exposure and health 
effect assessment. 
4 The roadmap development procedure 
This roadmap is a product of expert discussions that started in 2008 with the definition of the 
NanoImpactNet project plan (FP7-Grant 218539, www.nanoimpactnet.eu). In 2009, during a 
NanoImpactNet workshop in Lausanne, Switzerland, participants were asked to answer a 
series of questions (Table 1) related to the design of occupational health surveillance studies 
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for both short- and long-term monitoring of the health of workers exposed to or handing 
nanomaterials. 
Table 1 Initial questions about issues that a workers' health surveillance program needs to take into 
account: 
1. Assessing and recording exposure  
a. How to gather qualitative and quantitative information on exposure (nature of worker 
tasks, areas of workplaces, materials being handled, control measures in place, field 
studies etc) 
b. How to record and access this information 
2. Assessing and monitoring health / health surveillance 
a. How to define a harmonized approach for data recording and access 
b. How to identify “effects” to be monitored, preferably early markers of effect or 
indicators of biological response as opposed to final outcome (disease, death) 
3. Information dissemination 
a. How to raise awareness amongst relevant health professionals 
b. How to disseminate the results of the monitoring to workers and management 
c. How to provide support to policy makers and other decision takers 
The insight gained from the workshop was condensed into a report (11), which was shared 
with the audience of a NIOSH-organized meeting in Keystone, Colorado, in 2010 (12). 
Realizing the potential need for world-wide harmonisation, a global group of WHO 
Collaborating Centres and other partners was formed to extend that report’s ideas to create 
this roadmap. The roadmap presented here will also serve as a guide for nanomaterial-
related activities of the co-authoring researchers when preparing their contributions towards 
the implementation of the WHO-Action plan 2012-2017. 
5 The roadmap 
The present roadmap proposes a strategy to gain global acceptability by many different 
actors for occupational health studies in the field and to harmonize the collection and storage 
of data to yield maximum benefits for all the parties involved. It covers three main domains: 
exposure, health, and framework conditions related to risk management and study design 
(Figure 1).  
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APPROXIMATELY HERE: FIGURE 1 
Figure 1: Proposed key roadmap elements grouped into three action domains with relative timing. 
Considerable cross-talk and harmonisation efforts between these domains are required to create a 
global framework for occupational health (OH) studies. For several elements, nanomaterials pose 
special challenges related to their complexity and the associated uncertainties. 
 
Global agreement is needed to outline the scope of information that should be collected for 
epidemiological studies in nanomaterial workers to address the following issues: 
• Exposure data measurements and models need to be evaluated and validated so that 
they are linkable to worker activities, task profiles, job titles, job descriptions, and 
industries on the one hand, and to production processes on the other.  
• Potential health concerns need to be identified and biomarkers of effects need to be 
assessed for detecting short- and long-term effects.  
• To facilitate global harmonisation, differences in risk assessment and management, 
but also data protection philosophies are important when designing epidemiological 
studies, identifying suitable cohorts and setting up exposure and health effect 
registries. 
Feedback loops are needed in each domain of activity. Furthermore, the groups working on 
harmonising the exposure, health, and risk management and study design domains need to 
be tightly linked and considerable cross-talk will be needed to ensure a meaningful and 
efficient harmonisation of methods and approaches. 
The roadmap focuses on occupational health studies in nanomaterial workforces. However, 
data collected following such a harmonized scheme will also be helpful to identify adequate 
risk management strategies, and to evaluate whether existing protective measures are 
efficient. The data will thus be interesting to industries using or producing nanomaterials, 
safety and health experts consulting for these companies, trade unions and politicians who 
need to respond to concerned constituents, and governmental and international bodies 
dealing with occupational health and safety issues surrounding nanomaterials. 
5.1 Exposure to nanomaterials 
Analysis and recording of exposure to nanoparticles is an important pre-requisite for the 
assessment of their health effects in workers. However, in most instances, this still 
represents one of the weakest stages in the risk management process.  
A key requirement for all studies is good quality data on exposed workers. Measurements 
need to be feasible and based on direct factual observations, taking into account the use of 
protective equipment and ventilation of facilities and processes that may limit exposures. 
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Ideally these exposure studies would be carried out by an occupational hygienist able to link 
data to activities and work processes, but in reality, this may not always be possible. A good 
nanomaterial exposure assessment should follow the steps below: 
1. Quantitative and qualitative assessment of potential exposures, including recording the 
number of companies and workers handling nanomaterials, quantities of materials used, 
handling procedures and whether nanoparticles are dispersed or in powder form during 
handling, for example. 
2. Identification of potential sources of nanoparticle emission and exposure, noting that 
“emission sources” are different from “exposure sources”, i.e. depending on the risk 
management measures in place, working with a source of nanoparticles does not 
necessarily correlate with worker exposure to the engineered nanoparticle of interest. 
This process should include an awareness of work practices. 
3. Agreement on and measurement of possible exposure parameters according to a 
harmonized protocol for all sites. This includes particle metrics and co-pollutants, and 
contextual information such as ventilation parameters, room size, protection strategies in 
use, duration of tasks, etc. 
4. Identification of descriptors for job titles, activities, processes and industry sectors, so as 
to build a multidimensional job-activity-exposure matrix for the estimation of personal 
exposure with statistical models. 
5. Incorporation of the results into industrial, national or international exposure registries. 
Before exposure registries can start receiving data, a consensus needs to be reached on: the 
nature and minimal quantity of exposure data and contextual information required; how the 
data should be collected and managed; where it should be stored (e.g. in exposure 
registries, which may need to be country-specific); and on who is allowed access and under 
which conditions (13). In addition, cross-talk with health specialists and epidemiologists is 
necessary to ensure that the parameters allow for the examination of potential links between 
exposure and effect. 
5.1.1 Qualitative assessment of exposure 
Exposure to nanomaterials is plausible at all stages of their life-cycle from formulation and 
production to application in products, use and disposal. The levels and duration of exposure, 
as well as the number of individuals affected will vary at each stage (14). Ideally studies 
would be based on sufficiently large populations, exposed to specific, relevant, well-
characterised nanomaterials at different levels and for different durations. However, this is a 
real challenge and not easily achievable in today’s nanotechnology industries. This is due to 
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a range of complex issues including costs, identification of workers handling nanomaterials, 
isolation of effects from specific manufactured nanomaterials versus those from other 
nanomaterials or chemicals involved in the process, and the fact that identified “high” 
exposures may lead to immediate corrective actions under the current precautionary stance 
being recommended by regulators and many other stakeholders (15).  
In reality, although the nanotechnology industries are growing, the number of nanomaterial 
workers is still quite small, the materials handled are heterogeneous, and the exposures 
diverse and continually changing. Information to identify where workers may be exposed can 
be derived from investigations of the types of materials companies are using, the types of 
workplaces and protective measures in place (16, 17), as well as larger, representative 
surveys to identify the sectors of industry that are using nanomaterials and that can provide 
information about the quantities involved (1). Currently, research facilities are one of the 
places where many people seem to be handling novel nanomaterials (18, 19). However, 
universities may not be ideal places for initial monitoring studies, because of highly varied 
work activities and the turnover of personnel. Manufacturing sites with fewer short-term 
changes may be preferable; where there is potential for different processes to give rise to 
different potential exposures (high versus low); where best practice in minimizing exposure to 
chemicals in general is already in place and a culture of safety exists. Exposure levels will 
also be industry-specific. An initial pragmatic solution may be to build on existing field 
studies, such as those being conducted by national occupational safety and health institutes 
(e.g. the US National Institute for Occupational Safety and Health (NIOSH)) (7) or by larger 
research projects (e.g. EU Framework 7 studies investigating exposure and protection 
strategies in the workplace, of which an overview is given in the NanoSafety Cluster 
Compenidum (4)). 
5.1.2 Agreement on parameters and measurement of exposure 
There is ongoing debate about which nanomaterial exposure parameters should be recorded 
(20). Good quality data are required, but it is not feasible to take large amounts of 
measurement equipment into busy workplaces on a routine basis; measurements need to be 
ongoing and practical. Furthermore, few validated data on which physico-chemical 
characteristics make nanomaterials hazardous or dangerous are available. As this debate 
continues, pragmatic approaches to exposure measurements are needed. For research 
purposes, a very detailed analysis of a wide range of parameters may be required, including 
mass, particle number, surface charge, surface reactivity, chemical composition, and 
characterization by electron microscopy (21, 22). However, in many other instances (e.g. for 
checking the efficiency of protective measures), measurement of mass, number, surface or 
charge of particles may be sufficient, regardless of the size distribution of the nanomaterials. 
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Ideally, any strategy should rely on practical personal and/or real-time monitoring of 
exposure to nanoparticles in areas where exposure has occurred or is very likely to occur at 
high concentrations. The best measurement methods are those that are specific to or highly 
correlated with the manufactured nanomaterial of interest. 
Around the world, leading research groups are using slightly different instruments and 
methods, and thus measuring different aspects of exposure to particles in the ultrafine or 
nanoscale range (23). Whilst the methodological details differ slightly (e.g., demonstrated by 
(20, 22)) approaches such as those followed in NEAT (24, 25) and NANOSH (22) can be 
integrated to produce a standardized protocol for general nanoscale materials, but they may 
not indicate exposure to specific nanomaterials. More investigation is needed for these 
generalized emission-based approaches to be shown to correlate with more traditional, filter-
based industrial hygiene measurements for specific engineered nanomaterials (26, 27). 
A series of workshops has been initiated to foster the process of harmonization and the 
integration of strategies for exposure measurement, analysis and storage of data (e.g. by 
NanoImpactNet and TNO in Europe, and by NIOSH in the US). Supplementing these 
measurement approaches, exposure can also be assessed using mathematical models 
involving key elements, such as the air dispersion characteristics, the manufactured 
nanoparticle emission rate, the worker’s distance from the emission source, and other 
factors. Mechanistic models to estimate exposure to nanoparticles have yet to be developed; 
however, concepts and tools for such models have been proposed (28) and can be used to 
structure the exposure assessment. For some specific activities, i.e. powder handling, a 
more detailed model has been developed (29). It is likely that in the near future further 
detailed models will be proposed although their calibration will remain a challenge. Currently, 
some initiatives are being carried out to harmonize strategies to analyse and report 
measurement data to facilitate future pooling and storage of data (23). Such retrievable data 
bases will play an important role in the process of model calibration and validation. 
5.1.3 Job-activity exposure models 
For the use of exposure models in epidemiological studies, it is essential that the models are 
activity- or task-based and provide exposure distributions to account for within- and between 
individual variation of exposure. Activity- or task-based models can then be used as building 
blocks for multidimensional job-activity exposure matrices for estimating personal exposure. 
An important condition for their use is that the description of tasks and activities is 
unambiguous. The same holds for the description of other input parameters, and contextual 
information. Another challenge will be to create a comprehensive overview of job titles and 
activities related to exposure scenarios, involving varying levels of exposure. Recent studies 
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suggest that the types of industries where manufactured nanoparticles are used and the 
types of exposure scenarios vary considerably (1, 30). Because the formation of cohorts for 
an epidemiological study may involve combining workers from different companies and 
possibly different countries, it is essential that job-activity exposure linkages are consistent 
among populations so that they can be included in pooled epidemiological studies.  
An important problem, however, is measuring small numbers of manufactured nanoparticles 
against a significant background of ambient ultrafine particles, where currently only costly off-
site analyses allow distinction of particle types (21). Contextual information about work 
processes, such as the kinetic, thermal and other energies involved, ventilation systems, and 
protective equipment, can help in modelling the contributions of task-specific exposure 
sources and existing hygiene measures. Here, a set of contextual information may replace 
such measurements for the purpose of large epidemiological studies where detailed particle 
assessments at every workplace would not be feasible. 
5.1.4 Incorporation into exposure registries 
For either short or longer-term assessment of worker health, good quality exposure data are 
required from workplaces where nanomaterials are routinely used. Thus, studies and 
exposure characterization campaigns should be promoted and the information gathered then 
needs to be shared broadly and made available to researchers investigating occupational 
health. Companies should be encouraged to keep records of work activities that are as 
detailed as feasible. Awareness of the need to collect exposure data and establish exposure 
registries should be raised as widely as possible and at a high level in businesses, with 
senior managers, safety officers and occupational health professionals, potentially via 
continuing professional development and other continuous education programs and 
professional societies (3). These results should then be incorporated into industrial, national 
or international exposure registries. An approach to creating such registries is discussed 
below. 
5.2 Occupational health effect assessment 
Workers' health should be monitored to ensure that their occupational interaction with 
nanomaterials does not result in any temporary or permanent harm. To monitor health 
effects, it is necessary to identify potential biomarkers and assess their relationship with 
exposure, differentiating between sub-clinical biomarker effects and health endpoints. 
Diversity of particle types is a major challenge. Effect markers may provide a useful strategy 
to address this issue. One proposed approach to addressing the diversity of particle types is 
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to de-emphasize exposure assessment in favor of grouping materials that produce similar 
pathways to disease (8). 
The following steps should be taken for collecting data for (large scale) occupational health 
studies: 
1. Identify the pathophysiological mechanisms potentially involved. Identification can be 
inspired from the mode of action of traditional particles and by deducing the likely 
consequences of novel physicochemical properties and nano-bio interactions. 
2. Once potential pathophysiological mechanisms are identified, it must be determined 
which bodily responses and diseases might be expected and which markers can be used 
to evaluate and validate their presence. As potential exposure to manufactured 
nanomaterials is very new the initial focus should be on short-term effects, i.e. effects that 
can be observed after a relatively short exposure duration. 
3. Some of the long-term effects that need to be assessed will correspond to the 
accumulation of low level effects over time, whilst the onset of others will be delayed such 
that a relatively short duration of exposure leads only much later to manifestations of 
effects. Markers are needed that are able to detect both types of long-term effects, and 
early in the disease’s progression when corrective actions are still possible. 
4. Health data will need to be collected and fed into health surveillance databases. It may 
be necessary to set up multiple interlinked databases to account for national differences 
in health systems and legislation. 
Before any (global) health database can be built, a consensus needs to be reached about 
the health endpoints, the markers and the methods to be included. The steps towards 
effective occupational health data collection, as described above, require feedback loops and 
also regular revision of the parameters needed and which exposure data can be made 
available.  
The implementation of sound risk management practice should not be delayed until long-
term health studies are completed. While long-term effects can be expected and confirmed in 
research studies only after nanomaterials have been present for some time, there is an 
immediate need to take precautionary steps to prevent long-term effects. For example, the 
recognition of the potential for diseases with delayed manifestation, such as mesothelioma 
from inhalation of some types of carbon nanotubes (31, 32), implies the need for immediate 
and strict precautionary measures. Research will have to confirm at a later stage that the 
recommended measures were indeed sufficient. 
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In parallel to health effect studies in workers, full assessment of nanomaterial hazards is 
required. This will require analysis of all the bodily systems potentially involved and 
represents one of the main toxicological challenges posed by nanomaterials. Much 
discussion has taken place on whether the current suite of regulatory toxicity tests is suitable 
for nanoparticles. NanoImpactNet, other European projects and the WHO Collaborating 
Centres are putting emphasis on the development and validation of in vitro approaches to 
test the health effects of nanoparticles as these reduce the use of experimental animals. 
Nevertheless it must be kept in mind that the unique aspects of nanomaterials may influence 
both the experimental design and outcomes.  
5.2.1 Identify potential health concerns and mechanisms 
When reducing the size of materials down to the nanoscale, physicochemical properties and 
interactions with biological systems change. There is considerable uncertainty with regard to 
the health consequences of exposure to these materials. This is partly due to lack of 
toxicological data, but also a consequence of the complexity of the nanomaterial-biotic 
system interaction (33). The testing and sponsorship programme of the Organisation for 
Economic Cooperation and Development (34) lists over 30 material properties as being 
potentially interesting for study. However, combining the number of physico-chemical 
properties with the number of health endpoints and testing methods results in an almost 
unsolvable task. Thus, to save time and efficiently use limited resources (not just financial, 
but also manpower and the number of institutions able to do such extensive testing) 
prioritisation is required. 
Prioritisation can be based on those characteristics believed to be most relevant and on 
effect mechanisms. The particle characteristics scientists most frequently cite as important to 
defining the interaction between nanomaterials and biological systems are size, surface 
properties, biopersistence (or solubility in biological media) and morphology (35). Size is a 
key aspect because small individual particles may translocate through membranes and 
tissue barriers allowing them to travel through the body and reach distal target organs such 
as the brain and liver (36). The aggregation/agglomeration state of nanoparticles may affect 
their potential for translocation while smaller primary particle size is associated with a larger 
surface area per unit of mass and thus a greater surface for biological interactions. Other 
relevant mechanisms via which nanomaterials are believed to cause effects are particles 
acting as transport vehicles (37-39), as leading to the generation of toxic substances such as 
free radicals and oxidative stress (40-42), and by the fibre paradigm, according to which long 
nanotubes are believed to act similar as long asbestos fibres (32, 43-45).  
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There is already a wealth of information in the epidemiological literature about exposure to 
"traditional" or "classic" particles and other (non-engineered) materials that fall within the 
EC's definition of nanomaterials. These workplace fibres, traditional nanomaterials and 
environmental airborne particulate matter give indications about the types of effects that 
should be considered - although as yet unknown effects should not be excluded. Studies on 
ambient particles suggest that particle exposure causes oxidative stress and inflammation 
resulting in the release of chemical messengers such as cytokines, and vasomotor factors 
with subsequent generalised inflammation, thrombosis, atherosclerosis, and potentially 
chronic obstructive lung disease and pulmonary fibrosis if the target organ is the lungs (46-
48). Studies of workplace fibres suggest that long, biopersistent fibres can lead over time to 
serious health outcomes such as mesothelioma, and consequently experts and some 
national authorities recommend precautionary measures similar to those for asbestos (15, 
49, 50). 
Experience from the occupational health monitoring of metal welders and flame cutters 
provides the most applicable example of an available data-set – although these workers are 
not exposed to one single nano-sized material, but to heterogeneous mixtures of highly 
reactive metal particles (some in the nanoscale size range) and gases. Reviews of the health 
effects of these fumes have, however, revealed few effects beyond modest decreases in 
lung function, airway irritation and pulmonary siderosis (51), with effects in the reproductive 
systems and central nervous system being inconsistent. The International Agency for 
Research on Cancer (IARC) has classified welding fumes and gases as category 2B, 
possibly carcinogenic with limited evidence in humans and inadequate evidence in 
experimental animals.  
In contrast to traditional particles, only limited data are available about novel nanomaterials. 
A group in Taiwan (52) has shown promising early results for the use of biomarkers of small 
airway damage and inflammation, as well as biomarkers of injuries to endothelium and 
sympathetic nerve activation among workers exposed to nanoparticles. Another study 
reported on seven Chinese workers handling a range of chemicals and nanoparticles who 
became ill, with subsequent pathological examinations of lung tissue revealing evidence of 
pulmonary inflammation, fibrosis and foreign-body granulomas, and nanoparticles were 
observed in pulmonary epithelial and mesothelial cells (53). However, poor occupational 
hygiene and the workers’ complex exposures preclude definitive conclusions about the 
contribution of nanoparticles to the effects observed.  
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5.2.2 Strategy to identify short and long term health effect markers 
Once potential endpoints or mechanisms of action have been identified, markers of effect 
need to be identified and validated. Biochemical tests or functional parameters to be 
assessed should be supported by consistent pathophysiological mechanisms. Attention 
could be focussed on exposure via inhalation and the skin, since these routes of exposure 
are better understood for non-nanoscale chemicals. Pulmonary and cardiovascular diseases 
(leading to increased morbidity and mortality amongst vulnerable groups in particular) have 
been linked to pollution and levels of ultra-fine particles, but their use as health endpoints for 
workers exposed to manufactured nanomaterials have limitations: they are non-specific (and 
certainly not nano-specific), have a high prevalence in the general population and share 
multiple non-occupational risk factors. Thus, information on exposure to these other risk 
factors would also have to be acquired to allow attribution of effects (and it would be only on 
the level of worker populations and not individuals). Although these factors make long-term 
studies more challenging to conduct and interpret, they have been used in studies of many 
occupational diseases.  
A variety of other potential short or long-term effect parameters have been proposed for a 
targeted assessment of personnel exposed to nanomaterials. These include heart rate 
variability, blood-clotting parameters, pro-inflammatory cytokines, up-regulation of adhesion 
molecules or antioxidant capacity, and biomarkers of pulmonary fibrosis (46, 54-56). These 
biomarkers are increasingly used to assess cardiovascular effects of fine particulate matter, 
quasi-ultrafine (i.e. PM < 0.25 µm) and primary carbon aerosols derived from traffic-related 
sources (57-60). These biochemical parameters have consistent pathophysiological 
mechanisms that have been investigated for combustion-derived ultrafine particles and 
diesel exhaust particles generated in laboratory settings (61). Although promising in 
epidemiological research as putative biomarkers of effect, these parameters are still not 
assessable for their predictive value of health risk at an individual level; they are not routinely 
applicable and need to be further validated. 
On the basis that the potentially relevant health endpoints that have been tentatively ascribed 
to manufactured nanoparticles are cardiovascular, pulmonary and inflammatory effects, 
possible health monitoring endpoints include: 
• Assessment of markers of exposure (e.g. presence of chemicals in the blood or the urine; 
this can readily be done for chemicals such as metals - strictly speaking not an endpoint). 
• Chemical changes in exhaled air or exhaled breath condensate suggested to reflect 
abnormalities of the airway lining fluid and lung inflammation (62-64) but also potentially 
exposure (65) 
14 
 
• Local effects: inflammatory changes, short-term respiratory changes, respiratory, eye or 
skin irritation, depending on the route of exposure/site of uptake (with special tests to 
study biopersistent long fibres such as some forms of carbon nanotubes).  
• Systemic effects to confirm cardiovascular changes and inflammatory mechanisms: 
heart-rate variability, platelet aggregation and other pro-thrombotic effects as well as 
cytokines and differential blood cell counts (54, 66). 
• Medical tests for early detection of health effects at a preclinical stage (e.g. clinically 
validated biological markers of cardiovascular, hepatic, renal, haematological or 
respiratory dysfunctions). 
We do not yet know whether or how such health effects may differ between chemically or 
structurally different particles at the nanoscale. To date, biomarkers of exposure cannot be 
adequately developed owing to the lack of consistent toxicokinetic studies of nanomaterials, 
which may be partly related to the enormous variability of surface properties for each type of 
nanomaterial and even between batches of the same material. However, it is likely that 
traditional biomarkers of exposure (e.g., mass quantification in serum or urine) will be more 
feasible for nanoscale metals than for carbonaceous nanomaterials. It is at present unknown 
whether manufactured nanoparticles in general, and carbon nanotubes in particular, can 
exacerbate pre-existing medical conditions or increase the susceptibility to certain diseases.  
5.2.3 Occupational health databases 
Health data collection should be tightly linked to exposure assessment. At a minimum, health 
data collection should be accompanied by a general exposure assessment at work places 
with identified risk potential. An occupational health database will need to allow the 
identification of exposed individuals and/or worker populations. Ideally, such a database 
would be held at a centralized data collection site with extended health screening at specific 
nanomaterial facilities. In addition to this basic data collection, targeted research studies will 
be needed with detailed exposure assessment and extended health effects monitoring, 
including mechanistic studies of the effects of nanomaterials. As for exposure, companies 
should be encouraged to keep records, awareness about the need for data collection should 
be raised, and the data should be incorporated into industry, national or international health 
registries. It would be useful if the databases can be linked to existing databases such as the 
national or international registries of death and cancer. 
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5.3 Harmonized study designs and data collection strategies 
The success of epidemiological studies for quantitative risk assessment depends on the 
quality of available exposure and health response data. To achieve a coherent approach that 
leads to valid conclusions, data collection needs to be defined in anticipation of future (ideally 
prospective) studies that will pool and compare different situations world-wide. Over the 
coming years, the following points need to be addressed: 
• Risk assessment and management cultures in different industrial sectors and countries 
need to be identified. 
• Data collection strategies and data protection philosophies and the associated legal 
systems of different countries need to be assessed, and strategies for dealing with them 
defined. 
• The most suitable epidemiological designs for different purposes need to be identified. 
• Exposure and health registries need to be established that can link to health surveillance 
systems or epidemiological research projects. 
It is unlikely that a single, global project on this scale could be set up to follow workers 
exposed to nanomaterials. However, a more modest approach with harmonized exposure 
and health registries could be established, recording details of workers’ activities, available 
information on exposure levels, the nanomaterials handled and health condition. Ideally, 
workers’ samples (e.g. blood, urine) would be stored for later analysis as more potential 
biomarkers of effect and exposure become available. 
5.3.1 Identify ethical, cultural and regional differences 
Any global data collection strategy needs to account for regional differences in existing 
technologies, exposure protection strategies, safety culture, data protection philosophies, 
and ethical aspects (67). These challenges are superimposed on the challenges and data 
needs for the conceptual models described above. For each of the recognized data collection 
needs, potential challenges for collecting (in the sense of being able to obtain) and defining 
(in the sense of using terminology that is free of sensitive connotations) such data needs to 
be identified. Differences in data protection laws might pose challenges to the collection (68), 
but also the pooling of data across frontiers. Usually, data can only be used for a pre-defined 
purpose and subjects' identities must not be revealed. In some countries individuals can 
request their data be withdrawn at any moment during the study, often there is an expiration 
date relating how long data can be stored, and data may only be shared with researchers 
located in countries that have at least the same regulation of data protection. 
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All of these challenges need to be described and addressed in a strategy on how to 
overcome the differences and gaps when defining the data needed for collection. Thus, 
information about cultural and regional differences should be an integral part of the 
recommendations for a globally harmonized data collection strategy. WHO Collaborating 
Centres and the OECD may have an important role to play in the collection of such data 
about cultural and regional differences. 
5.3.2 Define epidemiological designs 
Well conducted epidemiological studies are an important source of information to risk 
assessment as they provide directly relevant human data. Epidemiological studies face 
challenges due to uncertainties in exposure measurements, dose to the target organ, and 
health effects resulting from the interaction of cells with nanomaterials. Nevertheless, 
examples exist [e.g., radon-exposed miners (69) asbestos-exposed textile workers (70)] in 
which prospective cohort studies have produced data that form the basis of quantitative risk 
assessments.  
Currently, the number of workers facing a potential exposure to manufactured nanomaterials 
is not known. Major challenges in conducting prospective cohort studies in nanomaterial 
workers include developing a large cohort size and the long time periods required to draw 
firm conclusions regarding chronic health effects. In the interim, small-scale studies of 50 to 
100 workers could be conducted within the next 5 years to assess biomarkers of exposure or 
of early effect (9).  
Whilst there is currently no firm basis for the recommendation of targeted nano-specific 
occupational health surveillance for most manufactured nanomaterials, this should not be a 
reason for paralysis or inactivity. There are clear knowledge gaps and achievable 
recommendations can be made: 
• General health surveillance should target those working with nanomaterials where 
exposure is likely (e.g. processes that are not contained), and the systems for recording 
the processes and types of nanomaterials used by the workers should be improved. 
• Workplaces should apply measures to control exposure, containing particle emissions 
and deploying personal protective equipment for workers when appropriate if potential 
exposure to nanomaterials cannot be excluded. The measure should be recorded, ideally 
in a standardized reporting format, during occupational health studies. 
• Simple questionnaires could be used for self-reporting symptoms so that focussed 
studies can be undertaken for different types of nanomaterials and industries. 
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• Individual cases of ill-health in those working with nanomaterials should be scrutinised to 
assess whether nanomaterials are a likely attributable source of the ill-health. 
• Improved knowledge-sharing should be encouraged at a national and international level, 
through occupational health reporting networks. 
• Simple nanomaterial measurement techniques are required that can be applied under 
most occupational circumstances without advanced technical knowledge. 
• Use should be made of biological monitoring (where applicable). 
Overall, there is a clear need to gather experimental, clinical and epidemiological data in 
order to characterize the relationship between exposure and health outcomes, and to provide 
a basis upon which to build and explore the effectiveness of preventative measures.  
5.3.3 Health surveillance and setting up registries 
The rapid development of exposure registries will help to provide data for the epidemiological 
studies of the future (3, 71). However, there are currently no validated methods for health 
monitoring and reporting that are specific to nanoparticles, but existing approaches for non-
nanoscale substances could be adapted. In the UK, occupational health reporting systems 
have been developed, but they rely on reporting (sometimes self-reporting) of adverse 
outcomes and they rarely record information on exposure levels. Furthermore, if effective 
preventive approaches are adopted in workplaces handling nanomaterials, the number of 
expected adverse outcomes could be very small or even non-existent. In France basic 
information on worker health status is already being collected via mandatory occupational 
health surveillance, and this will be available in the future for retrospective studies (10). The 
approach recommended by NIOSH in the US is to consider the hazard and exposure levels 
of the nanomaterial when making a decision about whether to employ routine medical 
surveillance (72). 
Historically, in occupational medicine, the practice of health surveillance has represented the 
final step in a process based on the integration of both experimental and epidemiological 
studies that identify the hazards and are supported by the implementation of occupational 
exposure limits (OELs). Medical surveillance requires at least a qualitative risk assessment 
and can be implemented when a residual risk exists and when the target population has 
been clearly identified (72). One major issue is the correct classification of exposure 
situations and linking them to the medical records. Currently, validated or even calibrated 
exposure models are lacking, however, and the application of such models for estimating the 
exposure of individuals will be hampered by the lack of indications of within/ between 
individual (worker) variances. 
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While there are no specifically validated methods for the risk assessment of nanomaterials in 
the workplace, the occupational safety community may be under-utilising its existing 
knowledge in hazard and exposure control of ionising radiation, biological agents, 
pharmaceuticals, nuisance dusts and pollution (73). With technology developing so rapidly, it 
will be necessary to make continual re-assessments and re-evaluations of the risks to 
workers’ health and safety from nanotechnologies and nanomaterials in particular. It is 
suggested that existing regulations can address the emerging issues and potential hazards 
presented by nanoparticles in the workplace, and although some disagree with this view, 
guidance and codes of conduct have been produced by different organisations (e.g. 
European Commission, UK’s Health and Safety Executive (HSE) (15), and NIOSH (74)). 
Although incomplete, the body of toxicological evidence on manufactured nanomaterials 
suggests that occupational hygienists and health and safety professionals should 
recommend precautionary management measures in the workplace, including in research 
laboratories handling nanoparticles. 
Risk management of nanomaterials in the workplace would involve recognition of potential 
worker exposure and the implementation of measures to reduce or minimise it (75). 
Occupational health surveillance and epidemiological research can support the risk 
management process by assessing whether health effects can be found at levels believed to 
be safe, but also by identifying the risks to workers where the exposure is insufficiently 
controlled (3). Thus, health surveillance and epidemiology are important tools to ensure 
workers’ health. Medical screening constitutes just one part of a complete health and safety 
management program. NIOSH has published interim guidance on medical screening for 
workers handling nanomaterials (72), which discusses the value of medical screening for 
asymptomatic workers. A second NIOSH guidance document (50) describes the need for 
medical surveillance for carbon nanotubes, which demonstrate a specific hazard in 
toxicological studies. 
5.3.4 Harmonisation of studies 
To enable the harmonisation of studies, preparatory step such as the establishment of 
exposure and health effect registries may be needed. Occupational exposure and health 
registries have been used in public health for over 50 years, and are especially useful when 
the risks to workers are not well-defined. Recently, the Dutch Health Council and the Social 
and Economic Council of the Netherlands strongly recommended the establishment of an 
early warning system and exposure registries for nanomaterial workers 
(http://www.gezondheidsraad.nl/sites/default/files/Nanotechnologie2.pdf, 
http://www.gezondheidsraad.nl/sites/default/files/200818.pdf, 
http://www.ser.nl/~/media/DB_Adviezen/2000_2009/2009/b27741.ashx).  
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We propose generation of an international framework under which such registries could be 
developed with a harmonized format and interlinked across Europe and globally. The 
proposed actions and related objectives are shown in Table 2. 
Table 2 Central issues for study of workers' exposure and health 
Actions Objectives 
Collect, collate, analyze and evaluate existing 
accessible data on exposure and contextual 
information, including activity-based exposure profiles 
with regard to their potential use in cohort studies and 
protection strategies 
Review of existing exposure data to identify which 
risk management measures are most effective in 
reducing potential exposure, including during non-
routine operations/accidents 
Identify existing descriptors for job titles, activities, 
processes, and industrial sectors, and subsequently 
build a multidimensional job-activity-exposure matrix 
for the estimation of personal exposure 
Develop models to link job activities to potential 
exposure to allow to evaluate the effect of current 
risk management practices on exposure levels. 
Test the feasibility of using the proposed matrices 
in epidemiology studies. 
Identify and critically evaluate candidate biomarkers of 
effect and exposure to nanomaterials Evaluate and select candidate biomarkers to 
contribute to improved methods for health impact 
assessment, particularly for monitoring early health 
effects in exposed populations. 
Evaluate practical issues for use of biomarkers in 
epidemiological studies and/or health registries of 
nanomaterial workers 
Assess existing epidemiological studies as well as the 
most critical issues in designing epidemiological 
studies in nanomaterial workers 
Outline the needs and possibilities for building 
occupational epidemiological studies for workers 
dealing with nanomaterials. 
Test feasibility of the proposed study designs, using 
existing data formats 
Review and evaluate existing and emerging tools for 
early assessment and management of risks among 
workers exposed to nanoparticles, and provide 
guidance for their harmonization and improvement 
To obtain harmonized exposure and health effect 
monitoring that allows a better evaluation of the 
various existing risk management tools. It also may 
eventually help identifying potential risky materials 
and strategies for managing these risks in a 
conservative manner. Develop guidance for exposure and health registration 
to be used by SMEs 
Development of such registries would ideally occur on an international scale to increase the 
numbers of workers recruited, although national views and regulations on data gathering and 
security may complicate this. These problems could be avoided by establishing national 
registries that collaborate internationally. 
Such a system for international surveillance can be set up in analogy to initiatives done for 
assessment of background exposure in the normal population. Indeed, within the frame of 
the FP7 EU project COPHES and the Life+ supported project DEMOCOPHES a strategy for 
harmonized human biomonitoring in 17 EU countries is currently worked out. In parallel with 
which was done there, also for nanomaterials occupational exposure, a pilot monitoring 
program can be worked out to start organizing registries and/or measurements starting on a 
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limited scale. The study should be coordinated and steered by a limited group of a few 
partners who prepare the pilot study. In this context, it would be good to include partners of 
industry and occupational associations in this steering group. If there are enough resources, 
other participants can join and should be fully supported by providing all (technical) advice 
and/or training needed.  
To obtain wide acceptance and support for such approaches, communication will be a very 
important element. This communication needs to reach workers, managers and also policy 
makers and research funding agencies. It was recommended that communication about 
nanomaterial risks should adopt established concepts of risk perception and risk 
communication strategies (76). 
5.3.5 Check appropriateness of screening strategies 
When hazard data are absent (as with many nanomaterials), the question is whether it is 
possible or informative to initiate specific health surveillance for nanotechnology workers 
(71). Unnecessary health surveillance can be associated with risks itself if it leads to 
incorrect diagnoses, uncertain interpretation, and the perception that work may not be “safe” 
for workers. Criteria of appropriateness should therefore be assessed; i.e. any screening 
strategy for a worker health should be justified on the basis that either: (i) finding a medical 
condition at an earlier stage significantly improves the potential outcome compared to a 
situation with no screening; (ii) especially in the case of chronic diseases, it helps reduce the 
population’s exposure to a level that prevents the development of these early stages of 
disease; or (iii) the screening program is used as part of a wider strategy to ensure effective 
exposure control. 
A range of factors needs to be considered to determine whether implementing health 
surveillance in the workplace is appropriate. Among the existing criteria are assessment of 
the burden of suffering (which the precautionary approach aims to prevent), the accuracy 
and reliability of current test methods, the effectiveness of early detection in the absence of 
clear correlations to health endpoints from manufactured nanomaterials, and an assessment 
of the benefits versus any harm resulting from the screening itself. On the basis of these 
criteria, the known risks associated with some screening methods (e.g. chest x-rays or 
computed tomography) would have to be outweighed by the benefits, such as 
implementation of workplace risk management measures or preventative health 
interventions, before such a recommendation could be made. Routine screening has to be 
justified on the basis of a sufficient likelihood of the expected exposure to manufactured 
nanomaterials causing the condition in question; the absence of any indication of a risk 
attributable to nanoparticle exposure precludes conclusions on this point at present.  
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6 Conclusions / Recommendations 
To best understand and control their health and exposure risks of workers dealing with 
manufactured nanomaterials, studies of groups and cohorts of those workers are necessary. 
At the moment, the necessary framework conditions to conduct such studies are not in place. 
To provide a coherent approach and make future epidemiological research a reality, a well 
defined framework is needed for the careful choice of materials, exposure characterisation, 
identification of study populations, definition of health endpoints, and evaluation of the 
appropriateness of study designs. Particularly needed are: 
• A basis for prioritizing which engineered nanomaterials merit investigation (e.g., 
based on toxicological or inferential studies) 
• A consistent, evidence-based set of job titles and task-based exposure profiles for 
epidemiological studies (informed by actual individual workplace assessments) 
• A method for linking industry, company and job descriptors to exposure and 
consistent exposure metrics; this will need to provide recommendations on the type 
and format of data to be collected and how it can be interlinked so that future 
studies can use the data for developing exposure estimates for large cohorts of 
workers. 
• Criteria for potentially useful biomarkers and (pre)clinical parameters for 
epidemiological studies on workers in small and medium enterprises and 
transnational companies. Recommendations on the feasibility of human population 
studies based on these biomarkers. 
• Recommendations on the requirements for harmonized approaches for human 
biomonitoring and health effect studies tailored to nanomaterial workers. 
• Recommendations for harmonization and the improvement of tools for early 
assessment and management of risks, and for exposure registration. These should 
be made available to relevant stakeholders, including small and medium 
enterprises, along the global value chain. 
For either short or longer-term assessment of worker health, good quality exposure data are 
required from workplaces where nanomaterials are routinely used, and methods for 
collection of exposure data should be tested, validated and agreed internationally with some 
urgency. Concomitantly, field studies and exposure characterization campaigns should be 
promoted and information shared broadly. Companies should be encouraged to keep 
records of work activities that are as detailed as feasible, and if possible, full use should be 
made of simple sensors such as particle counters (recognizing that these are not at all 
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specific for the manufactured nanomaterial of interest). Awareness of potential hazards and 
the need to collect exposure data and establish exposure registries should be raised as 
widely as possible, potentially at a high level in businesses, with senior managers, safety 
officers and occupational health professionals, potentially via continuing professional 
development and other programs of continuing education. 
Although at present no nano-specific screening procedure exists for the medical surveillance 
of workers potentially exposed to nanoparticles, periodic general medical examinations are to 
be recommended, preferably based on non-invasive procedures. Increasing general health 
surveillance for these workers could lead to an earlier recognition of adverse effects and 
information about which symptoms should be followed in other similarly exposed workers. 
This might also lead to informative individual index cases being identified. 
There is an urgent need for further toxicological evaluation and physico-chemical 
characterization of all the types of nanomaterials currently handled in workplaces, and a 
determination of the relationship between particle characteristics and health effects so as to 
facilitate prediction of the effects of new materials, and to identify the most important 
exposure characteristics to be assessed. Biomarkers of exposure and health effects are also 
required, and novel, ideally point-of-care, detection techniques need to be explored for 
assessing those exposures, e.g. via determination of particle numbers or pro-inflammatory 
cytokines in exhaled breath condensate. 
In spite of the advances in establishing a conceptual framework leading to a higher degree of 
worker protection, epidemiological studies of workers potentially exposed to manufactured 
nanomaterials will be difficult to conduct, for both ethical and practical reasons. These 
include: the heterogeneity of nanomaterials used in occupational settings, the overlap in 
exposure between combustion- or pyrolysis-derived ultrafine particles and manufactured 
nanoparticles, the lack of standardized exposure metrics, the long time-frame required to 
develop informative exposure histories, and the international cultural differences related to 
surveillance systems, data recording and storage, and data protection. Further issues include 
how to distinguish health effects that may arise from exposure to nanomaterials from those 
due to exposure to other workplace hazards and potential toxicants, and the effects of 
multiple exposures and confounding factors, such as smoking and underlying health 
conditions. 
The proposed roadmap addresses a joint strategy and the flow of actions needed to achieve 
these goals. Such a joint strategy will ensure that the costs of action are not disproportionate 
to the potential benefits and, very importantly, that the strategy will be pragmatic and 
practical. The discussion has only just begun about the benefits and challenges associated 
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with the different potential approaches for occupational health surveillance and 
epidemiological studies for workers exposed to nanomaterials. However, results from such 
studies are needed for the assessment of nanomaterial workers’ risk and for evaluation of 
exposure controls. 
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